Illumina, Inc. (ILMN)
NASDAQ · Healthcare · Medical - Diagnostics & Research
Profile
Illumina, Inc.
- Exchange
- NASDAQ
- Ticker
- ILMN
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Country
- US
Illumina, Inc. specializes in delivering advanced genetic and genomic analysis tools, primarily through sequencing and array technologies. The company's offerings empower clients across various sectors to integrate genomic insights into both research and clinical environments, with applications spanning critical fields like life sciences, cancer diagnostics, reproductive health, agriculture, and innovative new domains. Illumina's portfolio encompasses specialized instrumentation and necessary consumables for genetic analysis, alongside comprehensive genotyping and sequencing services. They also offer instrument maintenance agreements, collaborate through development and licensing deals, and perform cancer detection tests. Its diverse clientele comprises leading genomic research facilities, universities, state-funded laboratories, medical centers, pharmaceutical and biotechnology firms, commercial molecular diagnostic providers, and businesses focused on consumer genomics. Illumina employs a two-pronged distribution strategy, selling directly to clients across North America, Europe, Latin America, and the Asia-Pacific. Additionally, it partners with life-science distributors to reach markets in Europe, the Asia-Pacific, Latin America, the Middle East, and Africa. Established in 1998, the company maintains its corporate headquarters in San Diego, California.
Key facts
Illumina, Inc.: key facts
- Illumina, Inc. (NASDAQ: ILMN) is a Medical - Diagnostics & Research company in the Healthcare sector.
- In fiscal 2025, Illumina, Inc. reported revenue of $4.3B and net income of $850.0M.
- Revenue fell 1.1% a year over the last 4 fiscal years.
- Free cash flow was positive in 5 of the last 5 fiscal years.
- Net income was positive in 2 of the last 5 fiscal years.
- Over the last twelve months, revenue was $4.5B and net income was $895.0M.
MonkScore
Illumina, Inc.'s MonkScore
MonkScore
MonkScore range: 90–100
as of October 2026
Sector rank: 33 of 628 in Healthcare
How this score is madeDisclaimer
Pillar ranges
- Growth60–70
- Profitability80–90
- Quality90–100
- Market Conviction90–100
- Safety80–90
The MonkScore runs from 0 to 100. Each range is one of ten 10-point groups, from 0–10 to 90–100.
Each pillar's range uses the same ten groups. The exact score and the pillar scores are in the MonkStreet app.
Fundamentals
Figures from the statements
Illumina, Inc.'s annual figures and the last twelve months, in USD. Last report: 27 September 2026.
| Figure | Last 12 months | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Revenue | $4.5B | $4.3B | $4.4B | $4.5B | $4.6B | $4.5B |
| Gross profit | $3.1B | $2.9B | $2.9B | $2.7B | $3.0B | $3.2B |
| Operating income | $1.0B | $864.0M | -$833.0M | -$1.1B | -$4.2B | -$123.0M |
| Net income | $895.0M | $850.0M | -$1.2B | -$1.2B | -$4.4B | $762.0M |
| Operating cash flow | $1.2B | $1.1B | $837.0M | $478.0M | $392.0M | $545.0M |
| Capital expenditure | -$173.0M | -$148.0M | -$128.0M | -$195.0M | -$286.0M | -$208.0M |
| Free cash flow | $1.1B | $931.0M | $709.0M | $282.0M | $106.0M | $337.0M |
| Total debt | $2.2B | $2.6B | $2.6B | $2.3B | $3.6B | $2.5B |
| Cash | $1.3B | $1.4B | $1.1B | $1.0B | $2.0B | $1.2B |
Revenue growth a year
- 1-year
- -0.8%
- 3-year
- -1.8%
- 4-year
- -1.1%
Compound growth between fiscal years.
Peers
Similar companies
- CareDx, IncNASDAQ:CDNAMonkScore range: 90–100
- Medpace Holdings, Inc.NASDAQ:MEDPMonkScore range: 90–100
- IDEXX Laboratories, Inc.NASDAQ:IDXXMonkScore range: 90–100
Score my top stocks · 14-day free trial · card required · not charged during the trial · cancel in one click
MonkStreet provides research, not investment advice.
Page built on 31 October 2026.